Publication: Response to initial treatment of low and intermediate risk gestational trophoblastic disease with methotrexate and folinic acid
Issued Date
2005-10-01
Resource Type
ISSN
01252208
01252208
01252208
Other identifier(s)
2-s2.0-30844473763
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.88, No.10 (2005), 1349-1354
Suggested Citation
Monnapa Tonanont, Peerapong Inthasorn, Dittakan Boriboonhirunsarn, Weerasak Wongthiraporn, Issaracha Suphanit Response to initial treatment of low and intermediate risk gestational trophoblastic disease with methotrexate and folinic acid. Journal of the Medical Association of Thailand. Vol.88, No.10 (2005), 1349-1354. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/16793
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Response to initial treatment of low and intermediate risk gestational trophoblastic disease with methotrexate and folinic acid
Other Contributor(s)
Abstract
Objectives: To evaluate the response and toxicity of methotrexate and folinic acid given as primary treatment of low and intermediate risk gestational trophoblastic disease (GTD). Material and Method: Medical records review was performed in patients who received methotrexate and folinic acid as a primary treatment of low and intermediate risk persistent GTD between January 1992 and December 2001. Response was defined as decline of beta human chorionic gonadotropin (hCG) to ≤ 5 mIU/ml (remission) after methotrexate and folinic acid treatment. Response rate was estimated and factors associated with response were evaluated. Results: Ninety four eligible patients were treated with intramuscular methotrexate and folinic acid. Complete remission was achieved in 64 cases (68%, 95%CI 58-78%). Mucositis (6.4%) and hepatotoxicity (6.4%) were the most common toxicity of methotrexate in the present study and none of these toxic effects was life threatening. Factors associated with response were initial serum hCG ≤ 10,000 mIU/ml and stage I disease. Conclusion: Methotrexate with folinic acid is effective treatment for low and intermediate risk GTD with minimal severe toxicity.